These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23653147)

  • 1. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
    Shibata SI; Chung V; Synold TW; Longmate JA; Suttle AB; Ottesen LH; Lenz HJ; Kummar S; Harvey RD; Hamilton AL; O'Neil BH; Sarantopoulos J; LoRusso P; Rudek MA; Dowlati A; Mulkerin DL; Belani CP; Gandhi L; Lau SC; Ivy SP; Newman EM
    Clin Cancer Res; 2013 Jul; 19(13):3631-9. PubMed ID: 23653147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
    Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
    Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
    Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors.
    Shah HA; Fischer JH; Venepalli NK; Danciu OC; Christian S; Russell MJ; Liu LC; Zacny JP; Dudek AZ
    Am J Clin Oncol; 2019 May; 42(5):413-420. PubMed ID: 30973373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
    Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
    Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
    Kendra KL; Plummer R; Salgia R; O'Brien ME; Paul EM; Suttle AB; Compton N; Xu CF; Ottesen LH; Villalona-Calero MA
    Mol Cancer Ther; 2015 Feb; 14(2):461-9. PubMed ID: 25504632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
    Heath EI; Forman K; Malburg L; Gainer S; Suttle AB; Adams L; Ball H; LoRusso P
    Invest New Drugs; 2012 Aug; 30(4):1566-74. PubMed ID: 21811833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
    Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM
    J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interaction between pazopanib and cisplatin regimen.
    Imbs DC; DiƩras V; Bachelot T; Campone M; Isambert N; Joly F; Jimenez M; Lafont T; Chatelut E
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):385-92. PubMed ID: 26779916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
    Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
    Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
    Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
    Heath EI; Infante J; Lewis LD; Luu T; Stephenson J; Tan AR; Kasubhai S; LoRusso P; Ma B; Suttle AB; Kleha JF; Ball HA; Dar MM
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):565-73. PubMed ID: 23344712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
    Takebe N; Beumer JH; Kummar S; Kiesel BF; Dowlati A; O'Sullivan Coyne G; Piekarz R; Rubinstein L; Fogli LK; Vaishampayan U; Goel S; O'Bryant CL; El-Rayes BF; Chung V; Lenz HJ; Kim R; Belani CP; Tuscano JM; Schelman W; Moore N; Doroshow JH; Chen AP
    Br J Clin Pharmacol; 2019 Nov; 85(11):2499-2511. PubMed ID: 31271459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
    Ramalingam SS; Kummar S; Sarantopoulos J; Shibata S; LoRusso P; Yerk M; Holleran J; Lin Y; Beumer JH; Harvey RD; Ivy SP; Belani CP; Egorin MJ
    J Clin Oncol; 2010 Oct; 28(29):4507-12. PubMed ID: 20837947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    Ramanathan RK; Egorin MJ; Takimoto CH; Remick SC; Doroshow JH; LoRusso PA; Mulkerin DL; Grem JL; Hamilton A; Murgo AJ; Potter DM; Belani CP; Hayes MJ; Peng B; Ivy SP;
    J Clin Oncol; 2008 Feb; 26(4):563-9. PubMed ID: 18235115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    Gibbons J; Egorin MJ; Ramanathan RK; Fu P; Mulkerin DL; Shibata S; Takimoto CH; Mani S; LoRusso PA; Grem JL; Pavlick A; Lenz HJ; Flick SM; Reynolds S; Lagattuta TF; Parise RA; Wang Y; Murgo AJ; Ivy SP; Remick SC;
    J Clin Oncol; 2008 Feb; 26(4):570-6. PubMed ID: 18235116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
    Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J
    Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.